• roche logo
  •  

    For each woman, there's a strategy

    The Roche Cervical Cancer Screening Portfolio helps protect her
    from cancer and from over treatment

 

THE ROCHE PORTFOLIO

The Roche cervical cancer screening portfolio of the cobas® HPV Test, CINtec® PLUS Kit, and CINtec® Histology Kit enables better patient outcomes.

Our portfolio helps identify high-risk genotypes together with individual results for the most aggressive HPV genotypes (16/18), identify those with transforming lesions (p16/Ki-67 positive) who need colposcopy, and confirm the presence or absence of CIN2+ lesions (p16-positive) in biopsies obtained during colposcopies.1,2,3 Learn more about our portfolio.

 

 

A Closer look at Screening Strategies

 

Normal cytology doesn’t always mean cancer free.

Cytology has a changing role in the screening of patients for cervical cancer. New strategies are needed to deliver improved patient care.

 

Pooled hrHPV testing prevents more cancer over time.

HPV-based screening reduces the incidence of cervical cancer within 4–5 years, compared with cytology-based screens.4,5 However, HPV-based testing only provides part of the answer.

 

  • Acronyms:

References:

1. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol.2011;121(3):505-509.

2. Schmidt D, Bergeron C, Denton KJ, Ridder R, European CINtec Cytology Study Group. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119:158-166

3. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R, European CINtec Histology Study Group. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133(3):395-406.

4. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection for high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012; 13:78-88.

5. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.